drugset
drugset / Trial / NCT05054140

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

NCT05054140 ↗

Phase 2 Unknown 450 enrolled Immunic AG
RandomizedParallel-groupDouble-blindTreatment

Summary

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER

Timeline

Start
2021-09-30
Primary completion
2025-01-07
Completion
2025-01-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Vidofludimus Small molecule — Oral

Indications

multiple sclerosis